Humira Recent News
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Plenty Of Opportunity In AbbVie, Even After Recent Run
UBS Downgraded AbbVie Shares; Here's What Changed Analysts' View
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside
Court Date For Litigation With Amgen And Other Expectations For AbbVie
The 5 Top-Selling Drugs In The World
Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth
Goldman's 7 Favorite Biotech Ideas For 2016
AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating
In Barclays' View, 2016's Second Half Looks 'Noisy' For AbbVie
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers
AbbVie Falling After Q4 Report, 2016 Guidance Affirmation
Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
What Are The Best-Selling Drugs Of 2014?